priors.science/reviews/systemic-sclerosis-treatment

Systemic Sclerosis Treatment

The current evidence on 20 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

20claims tracked
66primary papers reviewed
10 Aug 2026latest evidence review
Weeklyre-scored against new papers
0 Established · 15 Likely · 4 Uncertain · 1 Doubtful  |  four-reviewer panel · PICO Framework
ClaimStandingEvidence certaintyCorpus
Nintedanib slows forced vital capacity decline in systemic sclerosis-associated interstitial lung diseaseCluster 1Likely83%15
Mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-associated interstitial lung diseaseCluster 2Likely80%13
Cyclophosphamide improves forced vital capacity in systemic sclerosis-associated interstitial lung diseaseCluster 2Likely79%9
Haematopoietic stem cell transplantation gives superior survival versus cyclophosphamide in diffuse cutaneous systemic sclerosisCluster 6Likely79%5
Bosentan reduces digital ulcers in systemic sclerosisCluster 7Likely78%5
Mycophenolate mofetil has superior tolerability versus cyclophosphamide in systemic sclerosisCluster 2Likely77%10
Rituximab reduces skin score in diffuse cutaneous systemic sclerosisCluster 4Likely76%7
Endothelin receptor antagonists and phosphodiesterase-5 inhibitors in systemic sclerosis-associated pulmonary arterial hypertension survivalCluster 5Likely75%4
Nintedanib effect consistent with mycophenolate mofetilCluster 1Likely74%10
Rituximab stabilizes forced vital capacity in systemic sclerosis-associated interstitial lung diseaseCluster 4Likely74%6
Selexipag reduces pulmonary arterial hypertension morbidityCluster 5Likely74%5
Iloprost reduces digital ulcers in systemic sclerosisCluster 7Likely73%5
Angiotensin-converting enzyme inhibitors improve outcomes in scleroderma renal crisisCluster 8Likely73%5
Macitentan reduces worsening in systemic sclerosis-associated pulmonary arterial hypertensionCluster 5Likely72%4
Tocilizumab preserves forced vital capacity in systemic sclerosis-associated interstitial lung diseaseCluster 3Uncertain67%7
Tocilizumab reduces skin score in diffuse cutaneous systemic sclerosisCluster 3Uncertain60%7
Prior angiotensin-converting enzyme inhibitor use worsens scleroderma renal crisis outcomesCluster 8Uncertain56%5
Abatacept reduces skin score in diffuse cutaneous systemic sclerosisCluster 9Uncertain55%3
Baricitinib reduces inflammation in systemic sclerosisCluster 9Doubtful49%2
Track Systemic Sclerosis Treatment.
These claims are re-scored against new papers every week. Track this topic for the full review, including each claim’s challenge and the papers behind it.
Track this topic →
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely70–84%Well supported, with some gaps or indirect evidence.
Uncertain50–69%Mixed or limited evidence. Genuinely open.
Doubtful30–49%Little support; the weight of evidence leans against it.
Refuted< 30%The evidence contradicts it — confidently false as stated.